Rafaèle Tordjman, MD, PhD, is Special Advisor for Sofinnova Partners that she joined in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post-doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialization in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Nucana Biomed, MedDay, ObsEva [OBSV] – which went public on Nasdaq, Lysogene [LYS] – which went public on EuroNext Paris, and Enyo Pharma. She was also on the board of Ascendis [ASDN] – which went public on Nasdaq, DBV technologies[DBV] – listed on Nasdaq and EuroNext, Flexion Therapeutics [FLXN] – listed on Nasdaq, Corevalve, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter, HBI Ltd before being acquired by Meda.
Rafaèle is also founder and Chairman of the not for profit association, W.I.T.H (Women Innovating Together in Healthcare – http://with-association.com/)